Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive
research. Nowadays, only symptomatic treatments exist for this disease, all trying to …

Alzheimer's disease (AD) is a neurodegenerative old age disease that is complex,
multifactorial, unalterable, and progressive in nature. The currently approved therapy …

Cholinergic synapses are ubiquitous in the human central nervous system. Their high
density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic …

Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors
represents the main available approach to treat cognitive and behavioural symptoms of the …

The foundation of current Alzheimer's disease (AD) treatment involves pharmacological and
nonpharmacological management and care planning predicated on patient-centered …

Objective To investigate whether cholinesterase inhibitors (ChEIs) are associated with
slower cognitive decline in Alzheimer dementia and decreased risk of severe dementia or …

Alzheimer's dementia (AD) is increasingly being recognized as one of the most important
medical and social problems in older people in industrialized and non-industrialized …

Alzheimer's disease (AD) is the most common cause of cognitive impairment or dementia in
individuals older than 65 years and, with rising longevity, a worldwide pandemic of mild …

Butyrylcholinesterase is a serine hydrolase related to acetylcholinesterase that catalyses the
hydrolysis of esters of choline, including acetylcholine. Butyrylcholinesterase has unique …

Background: The effectiveness of the 5 US Food and Drug Administration–approved
pharmacologic therapies for dementias in achieving clinically relevant improvements is …